Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2025-522910-21-00
Authorised, not yet recruiting Phase III

A Phase 3b, open-label, multicenter, continued access study for participants transitioning from ViiV  Healthcare‑sponsored or ViiV  Healthcare‑collaborative parent studies for HIV treatment Appendix : Management of Participants from Parent Study BRIGHTE

2025-522910-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
Viiv Healthcare UK Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Virus Diseases
Decision date
05/10/2026
Enrollment target
5
Sites
Romania

Condition studied

HIV infection

Investigational medicinal product(s)

Rukobia 600 mg prolonged-release tablets

Every trial of Fostemsavir across our registers →

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

1. Reasons for discontinuation of study intervention;, 2. Incidence and outcome of SAEs;, 3. Incidence and outcome of AESIs (if collected in the applicable study appendix).

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522910-21-00 on CTIS ↗ ← All trials in the EU